Nkarta Therapeutics develops engineered allogeneic and CAR‑NK cell therapies built on proprietary NK cell expansion and cell‑engineering technologies pioneered by Dario Campana. Its lead programs include NKX101, an allogeneic NK therapy targeting NKG2D for hematologic malignancies and solid tumors, and a CAR‑NK program targeting CD19 for B‑cell malignancies. The company is advancing IND‑enabling studies and multiple early‑stage clinical trials and plans to use recent financing to support those programs. Nkarta also intends to develop additional product candidates from its broad NK engineering platform. Management expects to complete a GMP manufacturing facility in South San Francisco in 2020 to supply investigational product for early clinical trials. The company was founded in 2015 and is led by president and CEO Paul Hastings.

Total raised

$114M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2019